Cancer Research Cell Death Mechanisms and Cancer Therapy  EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Evans, R. J.
Right arrow Articles by Jones, C. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Evans, R. J.
Right arrow Articles by Jones, C. J.
[Cancer Research 63, 4854-4861, August 15, 2003]
© 2003 American Association for Cancer Research


Regular Articles

A P53-dependent, Telomere-independent Proliferative Life Span Barrier in Human Astrocytes Consistent with the Molecular Genetics of Glioma Development1

Rebecca J. Evans, Fiona S. Wyllie, David Wynford-Thomas, David Kipling2 and Christopher J. Jones2,,3

Department of Pathology, University of Wales College of Medicine, Heath Park, Cardiff CF14 4XN, United Kingdom


    ABSTRACT
 Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
An in vitro model, based on normal (primary) human astrocytes (NHAs), was used to investigate the nature of the selection pressures for events that occur during the progression of astrocyte-derived tumors and, in particular, the potential role of proliferative life span barriers (PLBs). As with fibroblasts, NHAs senesced with elevated p21WAF1 and senescence-associated ß-galactosidase activities. Unlike fibroblasts, replicative senescence (M1) occurred much earlier, after ~20 pd and was not bypassed by hTERT expression. Abrogation of p53 function, by expression of human papillomavirus type 16 E6, led to an extension of life span, implying that replicative senescence in NHAs was p53-dependent but telomere-independent. human papillomavirus type16 E6 expression promoted additional growth of up to 12 pd, until a second telomere-independent PLB (termed MINT) was imposed associated with elevated p16INK4A levels. A proportion of cells escaped from MINT lost p16INK4A expression and achieved approximately an additional 25 pd until a crisis-like third PLB (M2) was reached. Expression of hTERT in post-MINT cells allowed these cells to become immortal and bypass this third PLB. The in vitro PLBs appear, in order of occurrence, dependent upon p53, p16INK4A, and telomere erosion, a situation that mirrors an equivalent order of mutational events during tumor progression in vivo. This study describes a model that provides a plausible explanation for the selective pressures driving mutational events in this tumor type and provides direct evidence of a p53-dependent, telomere-independent PLB.


    INTRODUCTION
 Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Malignant gliomas, the most common form of primary brain tumors, are thought to develop by a process of clonal evolution, acquiring molecular abnormalities, including many that overcome the inherent restraints of replicative life span barriers of NHAs4 (1) . Indeed, the process of tumorigenesis in many tissues is likely to require the evasion of a number of such PLBs.

Two PLBs, replicative senescence (M1; Refs. 2 , 3 ) and crisis (M2; 4 ), have been well-characterized in vitro in many cell types, including HDFs. Under optimal culture conditions fibroblasts undergo ~40–70 pd (depending on donor age) before entering a stable proliferative arrest state (M1) in which they remain viable for many months or years (2) . HDFs can bypass M1 by expression of a variety of DNA tumor virus proteins, including SV40 T antigen (5 , 6) , and a combination of both HPV-16 E6 and E7 genes, both of which target a common set of cell cycle regulatory tumor suppressor gene products, notably p53 and pRB (7 , 8) . Fibroblasts that bypass M1 in this way are capable of at least an additional 30 pd, after which additional expansion is limited by the second PLB termed crisis or M2, which is characterized by widespread cell death. Escape from M2 depends on stabilization of telomere length by reactivation of telomerase or by an alternative mechanism (9 , 10) . Expression of the catalytic subunit of telomerase (hTERT) alone is sufficient to bypass M1 or M2 and immortalize fibroblasts (11) .

Additional investigation has revealed that intermediate arrest states (termed MINT) can be imposed through selective abrogation of either p53 or pRB alone (12) . The intermediate states of growth arrest induced by loss of p53 (MINTE6) or pRB (MINTE7) function are very different. MINTE6 is reminiscent of M1 senescence and is potentially mediated by p16INK4A expression, whereas the expansion of cell cultures at MINTE7 is limited by increasing cell death and a phenotype similar to M2 (12) . Similar MINT states have been observed in Li-Fraumeni syndrome fibroblasts (13) , where spontaneous loss of the remaining copy of wild-type p53 also results in growth arrest at a point intermediate between M1 and M2.

The initial aim of this study was to investigate factors affecting life span in astrocytes. It was designed in such a way as to recapitulate the genetic events during the clonal evolution of tumors in vivo, using serial analysis of both clonal and polyclonal populations, with extensive characterization of cells at all stages of their life span. Our results led to a model of multiple PLBs that is strikingly consistent with those suggested by the pattern of genetic changes associated with disease progression in vivo. This study also uncovered a novel p53-dependent, telomere-independent PLB.


    MATERIALS AND METHODS
 Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Cell Strains and Culture.
NHAs derived from fetal brain (NHA 5732; Clonetics) were routinely subcultured every 6 days in 75-cm2 flasks in astrocyte growth medium (Clonetics) containing 5% fetal bovine serum. Cells were reseeded after reaching confluence at 3500 cells/cm2. The medium was changed every 3 days, increasing to >6 days as cultures approached replicative senescence.

Retroviral Gene Transfer.
Genes were transduced into NHAs using amphotropic retroviral vectors. The catalytic subunit of telomerase, hTERT cloned into pBABE puro, was used as previously described (14 , 15) and the empty vector used as a control. A retrovirus expressing HPV-16 E6 protein (HPV-16 E6 neo; Ref. 7 ) conferring resistance to G418 was used, which allowed dual drug selection in later experiments. A retrovirus based on pBABE neo was used as a vector control. For infection, cells were plated in 60-mm dishes at a density of 105 cells/dish and 2 days later exposed to retrovirus-containing medium from near-confluent producer cells, containing Polybrene at a concentration of 8 µg/ml. Two days after infection, cells were serially diluted and replated at densities appropriate to produce polyclonal and monoclonal populations. For drug selection, G418 was used at a concentration of 400 µg/ml and puromycin at 2.5 µg/ml. To create dual infected cells, NHAs were infected sequentially with pBABE neo at pd 7, a G418-resistant pooled population expanded, and then infected at pd 13 with pBABE puro, at which point individual drug-resistant clones were isolated.

Detection of SA ß-Gal Activity.
Two days after plating on coverslips endogenous SA ß-gal activity (16) was assessed histochemically using 5-bromo-4-chloro-3-indolyl-ß-D-galactopyranoside as the substrate.

Assessment of DNA Synthesis by BrdUrd Incorporation.
Cells were plated onto coverslips and re-fed with Dulbecco’s modified Eagle medium 2 days before the assay. Cells were labeled by incubation in 50 µM BrdUrd for 1 h, after which nuclear incorporation was detected by immunoperoxidase immunocytochemistry as described previously (12) . The proportion of labeled nuclei (LI) was determined from a count of 500 cells taken from three coverslips and the SE of the proportion calculated.

Immunocytochemistry.
For p21WAF1 detection, NHAs were plated onto coverslips 2 days before analysis, fixed in 4% paraformaldehyde (10 min) and then pretreated with 50 mM glycine (10 min), 0.2% Triton X-100 (10 min), and 0.3% H2O2 (3 min). Nonspecific binding was blocked with 2% horse serum (30 min). Anti-p21WAF1 antibodies (clone 6B6; Cambridge Bioscience, Cambridge, United Kingdom; Ref. 17 ) were applied followed by a mouse-specific avidin-biotin-peroxidase system (Novocastra). Sites of antibody binding were visualized by the deposition of brown polymer after incubation in diaminobenzidine-hydrogen peroxide solution.

Telomerase and Telomere Length Assays.
TRAP assays and TRF length measurements were performed as described previously (18) . For TRAP assays, protein extracts were prepared from trypsinized NHAs and diluted to 5000 cell equivalents/reaction, where an oligonucleotide substrate was extended by telomerase, amplified by PCR, and products separated on 10% polyacrylamide gels. Products were visualized by Sybr Gold staining and detected by fluorimaging (Storm; Amersham Biosciences). For TRF analyses, 1 µg of genomic DNA extracted using a Nucleon kit (Amersham) was digested with HinfI and RsaI, separated on 0.5% agarose gels, which were denatured with 0.5 M NaOH and neutralized with 0.5 M Tris (pH 8.0) containing 1.5 M NaCl. The gels were dried and probed with 5'-CCCTAACCCTAACCCTAA-3' end-labeled with {gamma}32P-ATP. TRFs were detected by phosphorimaging.

Immunoblotting.
Cells were lysed for 5 min at 4°C in a buffer containing 1% NP40 in 150 mM NaCl, 50 mM Tris (pH 8.0), 5 mM EDTA supplemented with 1 mM phenylmethylsulphonyl fluoride, 0.01 mg/ml aprotinin, and 0.01 mg/ml leupeptin. Protein samples (20 µg each) were separated on 12% SDS PAGE gels and transferred onto polyvinylidene difluoride (Millipore). Primary antibodies raised against p53 (DO-1 (19) , p27KIP1 (K250; Transduction Laboratories), p21WAF1 (clone 6B6; Cambridge Bioscience; Ref. 17 ), and p16INK4A (DCS 50; Calbiochem; Ref. 20 ) were applied. Antibody binding was detected by goat antimouse peroxidase conjugate and visualized by the enhanced chemiluminescence detection system (Amersham Biosciences). The filter was subsequently stained with India ink and loaded protein quantified by using a Bio-Rad imaging densitometer with Molecular Analyst software. All immunoblots were performed at least three times.

Analysis of Methylation Status of p16INK4A Promoter.
Genomic DNA was modified using a CpGenome DNA modification kit followed by detection using a p16INK4A CpG WIZ Amplification kit (both Intergen). Methylation-specific PCR primers (21) were used to distinguish methylated bisulphite-modified DNA from unmethylated modified DNA at a 5' CpG island in the p16INK4A promoter region. The following changes were made to the manufacturer’s protocol. DNA (2 µg) was modified with bisulphite and resuspended in 20 µl of a 10 mM Tris buffer, pH8, containing 1 mM EDTA buffer. DNA (200 ng) was added to PCR reactions and incubated at 95°C for 5 min (hot start) before addition of 1 unit of Taq DNA polymerase (Promega). PCR products were separated on 1.5% agarose gels.


    RESULTS
 Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Replicative Senescence in NHAs.
NHAs were obtained from a commercial source (at a point designated pd 0) and were routinely cultured until they reached a state of replicative senescence (M1). Senescence occurred after 20 pd and a period of ~55 days (Fig. 1)Citation . Morphologically young NHAs (pd 8) were thin and elongated (Fig. 2A)Citation . Approximately 50 ± 2.6% of cells were immunopositive for p21WAF1 staining (Fig. 2B)Citation and showed a BrdUrd LI of 31 ± 2.3% (Fig. 2C)Citation after a 1 h pulse, whereas 46 ± 2.2% of cells showed SA ß-gal (Fig. 2D)Citation .



View larger version (11K):
[in this window]
[in a new window]
[Download PPT slide]
 
Fig. 1. Replicative life span of primary NHAs. Normal astrocytes ({blacksquare}) were routinely cultured over a period of 75 days. During that time they reached replicative senescence (M1) after 55 days.

 


View larger version (88K):
[in this window]
[in a new window]
[Download PPT slide]
 
Fig. 2. Characterization of proliferating and senescent NHAs. A series of cell cycle regulators and markers of proliferation were analyzed in young (pd 8, A–D) and senescent (pd 20, E–H) NHAs: (A and E) representative photomicrographs; (B and F) expression of p21WAF1 detected by immunocytochemistry (positivity indicated by brown peroxidase reaction product); (C and G) incorporation of BrdUrd; (D and H) senescence-associated marker SA ß-Gal assessed by 5-bromo-4-chloro-3-indolyl-ß-D-galactopyranoside histochemistry (blue reaction product). In some panels, nuclei are lightly counterstained with hematoxylin to aid visualization. Bars represent 100 µm.

 
At senescence the characteristically enlarged and flattened appearance of senescent cells with associated granular nuclei (Fig. 2E)Citation was accompanied by high p21WAF1 (85 ± 1.6%) immunostaining (Fig. 2F)Citation , a low BrdUrd LI (1 ± 0.5%; Fig. 2GCitation ), an elevated SA ß-gal index (90 ± 1.3%; Fig. 2HCitation ).

Replicative Senescence in NHAs Is Telomere Independent.
Telomere length was analyzed in astrocytes at pd 8, 16, and 20 using the TRF assay (18) . The assay detects all telomeric sequences that are displayed as smears, indicative of differences in telomere length between both individual chromosomes and cells within the population. The TRF assay indicated that there appeared to be a modest amount of telomere shortening during the replicative life span of the culture (Fig. 3A)Citation . In the M1 sample (20 pd), a proportion of the smear comprises lower molecular weight species. However, the overall signal is of a higher molecular weight with a wider distribution of telomeres compared with senescent HDFs where TRFs as low as 2 kb are detected (22) .



View larger version (57K):
[in this window]
[in a new window]
[Download PPT slide]
 
Fig. 3. Replicative senescence in NHAs is telomere independent. A, TRF analysis of NHAs during proliferation and senescence. Genomic DNA was digested, separated, and probed in situ with a telomere repeat-specific probe. M, 32P-labeled {lambda} HindIII digest; Lanes 1–3, NHA DNA extracted from cells at 8, 16, and 20 (senescent) pd, respectively. B, TRAP assays of NHA infected with hTERT, the catalytic subunit of telomerase, or a vector control. Cell extracts (5000 cell equivalents/reaction) were assayed for telomerase activity using the TRAP assay. C, control telomerase-positive 293 cell extract. When extracts are pretreated at 85°C for 10 min, telomerase activity is abolished (negative control). All samples successfully amplified a control substrate (internal telomerase amplification standard; *). Sample 1, NHA.hTERT-pooled colonies. Sample 2, NHA.puro pooled colonies. C, Bar chart showing the total life span of NHA.hTERT ({blacksquare}) and NHA.puro clones ({square}) in vitro. Cells were infected at pd 13. D, phase contrast photomicrographs of NHA.puro (i) and NHA.hTERT at pd 20 (ii).

 
Previously we immortalized HDFs by infecting presenescent cells with an amphotropic retrovirus coexpressing hTERT and a puromycin resistance gene (14) . Immortalization was associated with detectable telomerase activity and telomere stabilization. To determine whether M1 in NHAs was similarly telomere dependent, cells at pd 13 were infected with pBABE hTERT or with pBABE puro as a control. Infected cells were then seeded at a range of densities in puromycin to allow selection of pooled colonies and individual subclones. S100 cell extracts were prepared from pooled populations of cells infected with pBABE hTERT (designated NHA.hTERT) and pBABE puro (NHA.puro) for analysis in TRAP assays. Telomerase activity in NHA.hTERT cells was confirmed by the presence of a DNA ladder with a periodicity of 6 bp that was also present in a control HEK293 cell extract and absent in NHA.puro (Fig. 3B)Citation .

These data showed that forced expression of hTERT in NHAs conferred telomerase activity on normally negative NHAs. Twenty-two individual NHA.hTERT subclones and 26 NHA.puro subclones were isolated and their proliferative life spans determined (Fig. 3C)Citation . NHA.hTERT subclones underwent an additional 5–12 pd after infection similar to NHA.puro that accumulated an additional 5–11 pd, with no significant difference between the two sample sets (P = 0.8). Therefore, reactivation of telomerase in NHAs failed to confer an extension of life span. Furthermore, at the end of their life span, both cell populations were morphologically similar (Fig. 3D)Citation and had the appearance of cells in M1. Therefore, unlike in fibroblasts, hTERT expression failed to extend the replicative life span of NHAs.

Replicative Senescence in NHAs Is p53 Dependent.
Although hTERT expression in HDFs allows these cells to become immortal, ablating the function of either or both of the tumor suppressor proteins pRB and p53 can also confer significant extension of cellular life span (12) . M1 in astrocytes was associated with high levels of p21WAF1 expression, suggesting that senescence was p53 dependent (Fig. 2F)Citation . To test this hypothesis, HPV-16 E6, which targets p53 for degradation, was introduced into NHAs at pd 7 using a neoR amphotropic retrovirus or the empty vector as a control. Infected cells were then seeded at a range of densities in G418 to allow selection and analysis of pooled populations and individual colonies. NHAs infected with HPV-16 E6 (designated NHA.E6) initially divided rapidly, showed similar morphology to young cells, and they continued to divide past the point at which NHA.neo cells entered M1. When analyzed at a point after the control NHAs senesced, the E6 cycling populations show morphology (Fig. 4A)Citation , similar to young astrocytes (Fig. 2A)Citation and as expected low levels of p21WAF1 expression were seen (8 ± 1.6%) consistent with E6 abrogation of p53 function (Fig. 4B)Citation . The cells had a BrdUrd LI of 31 ± 2.7% (Fig. 4C)Citation and a SA ß-gal index of 40 ± 2.8% (Fig. 4D)Citation .



View larger version (43K):
[in this window]
[in a new window]
[Download PPT slide]
 
Fig. 4. Abrogation of p53 function extends the life span of NHAs past M1 until an additional PLB is reached. Top panel (photo montage), HPV-16 E6 protein was introduced into NHA before M1. The consequent abrogation of p53 function allowed the cells to reenter the cell cycle (E6 cycling A–D) until growth arrest occurred at MINT (E–H): A and E, representative photomicrographs; B and F, expression of p21WAF1; C and G, incorporation of BrdUrd; D and H, senescence-associated marker SA ß-gal. Bars represent 100 µm. Bottom panel, bar chart showing the total life span of NHA populations infected at pd 7 and 19 with either a retrovirus expressing HPV-16 E6 and a neomycin resistance gene ({blacksquare}) compared with controls infected with a neomycin resistance gene alone ({square}).

 
Extension of Life Span in NHAs after E6 Expression Ends in a Stable State of Growth Arrest (MINT).
Additional analysis of NHA.E6 subclones revealed that life span extension associated with p53 inactivation was finite. Between 37 and 46 days after infection (at 7 pd), both pooled and individual NHA.E6 cells entered a state of growth arrest similar to M1. This was reminiscent of a similar state that we have previously reported in E6 transduced fibroblasts (12) that we termed MINT (i.e. intermediate arrest state between M1 and M2). NHA.neo controls entered M1 with total life spans of 19–22 pd, including the period spent in culture before infection. Expression of E6 extended the total life span of NHA.E6 clones to 27–29 pd (Fig. 4)Citation .

In another experiment NHAs were infected 1–2 pd before senescence (19 pd). As predicted, these reached MINT after a similar life span extension (Fig. 4)Citation . Populations of pooled colonies reached MINT after an extra 12 pd (data not shown). Therefore, overall E6 confers a limited but statistically significant life span extension of 7–12 pd (P < 0.001). Astrocytes at MINT were morphologically very similar to cells at M1 and were enlarged and flattened with a characteristic granular cytoplasm (Fig. 4E)Citation and p21WAF1 levels remained very low (1 ± 0.7%; Fig. 4FCitation ), indicating continued abrogation of p53 by HPV-16 E6. The cells had a low BrdUrd LI (3 ± 1.2%, Fig. 4GCitation ) and a very high SA ß-gal index (90 ± 2.1%; Fig. 4HCitation ).

Expression of hTERT in Cells Expressing HPV-16 E6 Fails to Prevent MINT.
M1 senescence in NHAs was associated with, but not dependent upon, telomere erosion (Fig. 3A)Citation . Unless telomerase is reactivated, the additional growth past M1 induced by E6 expression would be expected to be accompanied by ongoing telomere erosion, raising the possibility that MINT is telomere dependent. NHA.E6 cultures at pd 13 were thus infected with pBABE.hTERT using the puromycin resistance gene as a second selectable marker to yield cells termed NHAE6.hTERT. Control NHA.E6 cultures were also infected with a retrovirus carrying the puromycin resistance gene alone, yielding cells termed NHA.E6.puro. Drug-resistant populations were expanded on a clonal basis. Six independent clones were analyzed and TRAP assays confirmed the NHA.E6.hTERT cells were telomerase positive (data not shown). NHA.E6 cells were telomerase negative (data not shown). All NHA.E6.hTERT clones entered a MINT-like state after a similar number of pd as NHA.E6, indicating that growth arrest was independent of telomerase status (data not shown).

Frequent Escape from MINT Associated with Loss of p16INK4A Expression.
Unlike M1, from which we never observed spontaneous escape (Fig. 5, A–D)Citation , the E6 induced MINT state frequently failed to act as a permanent barrier to proliferation (Fig. 5, G and H)Citation . In several examples, both clonal and polyclonal cultures began to reenter the cell cycle after residing at MINT for a period ranging between 15 and 40 days (Fig. 5, G and H)Citation . These cells remain telomerase negative (data not shown). TRF analysis of cells that had escaped from MINT indicated that this new burst of proliferation was associated with additional telomere shortening (Fig. 5I)Citation . The cells continued to divide until they reached an M2 or crisis-like state, presumably because of critical telomere erosion (Fig. 5, G, H, and J)Citation . No additional stable or transient life span barriers were observed during progression to M2.



View larger version (44K):
[in this window]
[in a new window]
[Download PPT slide]
 
Fig. 5. Escape from MINT ends in crisis and is associated with additional telomere shortening. Representative growth curves of a series of NHAs infected with pBABE neo control retrovirus. Pooled (D) and three individual control subclones (A–C). Representative growth curves of a series of NHAs infected with HPV-16 E6 retrovirus. Pooled (H) and three individual subclones (E–G). Note escape from MINT in G and H after a period of quiescence ends in M2 crisis represented by a dotted line that intersects abscissa at the point where no live cells were observed in culture dishes. I, TRF analysis of an NHA.E6 and NHA.E6.hTERT clone. Lanes 1–3, NHA.E6 after escape from MINT at 38, 49, and 60 (crisis) pd, respectively; Lane 4, NHA.E6.hTERT at 60 pd; Lane M, 32P labeled {lambda} HindIII digest. J, phase contrast photomicrographs of a post-MINT NHA.E6 cycling (i) and NHA.E6 crisis/M2 (ii) pooled colonies population; infected at 7 pd. Bars represent 100 µm.

 
The observation that escape from MINT was a spontaneous event, independent of any additional experimental intervention, suggested that factors regulating cell cycle control may have been affected. Analysis of the expression of key cell cycle regulators by immunoblotting was undertaken during the various phases of astrocyte growth. P53 protein was detectable in proliferating astrocytes in cells at pd 15 and M1 and, as expected, expression was greatly reduced in NHA.E6 cells at MINT (Fig. 6A)Citation . The expression of p21WAF1 mirrored that seen immunocytochemically with high levels at M1 (Fig. 2F)Citation and loss of expression when E6 was present (Figs. 4, B and FCitation , and 6BCitation ). Analysis of p27KIP1 in NHA revealed that there was a ~3-fold decrease in NHA.E6 cells at MINT compared with those at M1 (Fig. 6B)Citation . There was no detectable change in p27KIP1 levels in cells that escaped from MINT.



View larger version (59K):
[in this window]
[in a new window]
[Download PPT slide]
 
Fig. 6. Analysis of cell cycle regulators at various stages of NHA life span. Protein extracts were prepared from NHAs at pd 15 and 20 (M1) and from NHA.E6 at pd 32 (MINT) and 35 (post-Mint), separated on SDS polyacrylamide gels and transferred onto polyvinylidene difluoride membranes. A, membrane probed with (i) anti p53 (DO-1) or (ii) anti-p16INK4A (DCS 50) antibodies. The level of protein loading was determined by India ink staining (iii). B, membrane probed with (i) anti p27KIP1 (K250); (ii) anti p21WAF1 (6B6); and (iii) anti p16INK4A (DCS 50) antibodies. The level of protein loading was determined by India ink staining (iv).

 
The most striking changes in cyclin-dependent kinase inhibitor expression were seen when p16INK4A was analyzed. Expression increased 30-fold at M1 compared with presenescent-proliferating cells, with a slight (<2 fold) additional increase at MINT (Fig. 6A)Citation . Escape from MINT was initially associated with reduced p16INK4A expression, as shown by NHA.E6 post-MINT cycling cells at 35 pd, where p16INK4A levels are ~6-fold reduced compared with MINT (Fig. 6B)Citation . This underestimates the degree of p16INK4A down-regulation measured on a per-nuclei basis (the presumed site of action) because of the reduced total cell volume of cycling post MINT cells. The residual p16INK4A expression in these initial post-MINT samples is mostly likely explained by the presence of p16INK4A-positive MINT cells still present in these mixed cultures. With additional growth of post-MINT cells, these residual MINT cells would be expected to be diluted out, and indeed, p16INK4A levels rapidly decrease to undetectable levels with ongoing proliferation (data not shown and Fig. 7BCitation ). Thus, the most likely conclusion is that escape from MINT is associated with loss of expression of p16INK4A. In astrocytes, p16INK4A is the only cell cycle regulatory protein analyzed where levels change significantly when the cells escape from MINT.



View larger version (28K):
[in this window]
[in a new window]
[Download PPT slide]
 
Fig. 7. Loss of p16INK4A expression in telomerase-positive NHA.E6 hTERT cells is associated with immortality. A, representative growth curves of a series of NHAs coinfected with HPV-16 E6 and either hTERT or control retroviruses. Two individual control subclones ({triangleup}) and two individual subclones infected with HPV-16 E6 and hTERT ({bullet}, {blacktriangledown}), which continue to proliferate and can be considered immortal. B, immunoblot of NHA expressing HPV-16 E6 at MINT and two representative NHAE6.hTERT immortal subclones at pd 88 and 65 probed with anti-p16INK4A (DCS 50) antibodies (i). The level of protein loading was determined by India ink staining (ii). C, down-regulation of p16INK4A expression is associated with promoter methylation. i, unmethylated primer set was used to amplify bisulphite modified unmethylated p16INK4A DNA. ii, methylated primer set was used to amplify methylated bisulphite-modified p16INK4A DNA. Lane 1, (i) methylated and (ii) unmethylated control DNA; Lane 2, NHA pd 6; Lane 3, NHA.E6 clone pd 43, and Lane 4, NHAE6.hTERT clone pd 145.

 
NHAs That Escape from MINT and Express Telomerase Are Immortal.
Dual infections of NHAs with retroviral vectors expressing hTERT and E6 established that MINT was independent of telomere status (see above). However, as expected, cells expressing hTERT and E6 eventually escaped MINT and resumed proliferating (Fig. 7A)Citation . All NHAE6.hTERT clones had long telomeres by the time they had progressed past MINT (the earliest time at which samples could be assessed; an example of one clone is shown in Fig. 5ICitation ). This telomere extension is particularly striking when comparing an NHA.E6.hTERT clone at 60 pd to a NHA.E6 clone at crisis after the same number of divisions (Fig. 5I)Citation . The growth of two NHA.E6.hTERT clones is shown in Fig. 7ACitation . To date, these have accumulated >170 pd and continue to divide and thus can be considered immortal. Analysis by immunoblotting of these clones at pd 88 and 65 showed undetectable levels of p16INK4A expression (Fig. 7B)Citation , implying that escape from MINT in cells expressing telomerase was also dependent on loss of this cyclin-dependent kinase inhibitor. The potential mechanism of p16INK4A down-regulation was investigated. The methylation status of the p16INK4A promoter was determined using bisulphite modification followed by PCR (21) . Methylated p16INK4A was present in cells that had escaped MINT (Fig. 7CCitation , Lane 3) and subsequently become immortal after hTERT expression (Fig. 7CCitation , Lane 4). Thus, a combination of a loss of p16INK4A expression, abrogation of p53, and maintenance of telomere length appears necessary for cellular immortality in NHA.


    DISCUSSION
 Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
A Novel PLB in Human Astrocytes.
The in vitro proliferative capacity of primary human cells varies widely between cell types. Without intervention it can be very low (e.g. thyrocytes, ~3 pd; Ref. 23 ) or relatively high (e.g. fibroblasts, >70 pd; Ref. 2 ). Human astrocytes have been reported to have a proliferative life span somewhere in between these two extremes (24) . In our hands, NHAs achieved ~20 pd before entering replicative senescence. This state was reminiscent of M1 senescence in fibroblasts, being associated with high p21WAF1 and SA ß-gal-labeling indices.

NHAs are telomerase negative, but although some telomere erosion is seen in the cell divisions before senescence in NHAs, the final arrest state does not appear to depend on telomere erosion. Previously, we have shown that forced expression of telomerase (using a retroviral vector encoding hTERT) is sufficient to immortalize HDFs (14 , 15 , 25) . In contrast, similar experiments in NHAs did not lead to any detectable extension of cellular life span, despite successful delivery of telomerase. We thus conclude that this first senescence-like PLB does not require telomere erosion.

Interestingly, some researchers have reported immortalization of NHAs after forced expression of telomerase. However, whereas in this study, we followed several independent hTERT-expressing clones, these previous studies focused on bulk pooled colonies (24 , 26) . For this reason, it cannot be discounted that in these other studies additional spontaneous changes occurred within one or more cells within this population, conferring a growth advantage, which then expanded to become predominant in the culture. This possibility, although not commented on previously, is made all of the more plausible by our data on subsequent PLBs in astrocytes. Our own data on clonal cultures, which clearly demonstrate the failure of hTERT to confer life span extension in any of the 22 NHA clones isolated, strongly implies that M1 senescence is telomere independent and that telomerase expression alone is not sufficient to immortalize primary astrocytes.

NHAs are not the first cell type to show telomere-independent senescence. Although telomere maintenance is ultimately necessary for cellular immortality, several other cell types do not show life span extension after forced expression of telomerase. Instead, before telomere erosion becomes a barrier to cell division, they enter a telomere-independent growth arrest state. Examples include thyroid follicular epithelial cells (25) , pancreatic islet ß cells (27) , keratinocytes (28) , mammary epithelium (29) , and uroepithelial cells (30) . Interestingly, where tested, many of these cell types show no alteration in their cellular life span after experimental abrogation of p53 function (31 , 32) . Unexpectedly, however, our own data (using HPV-16 E6 oncoprotein) reveals that NHA cellular life span is extended, by ~12 pd, after abrogation of p53 function. This provides a highly unusual example of a human cell that shows p53-dependent but telomere-independent senescence. Although a p53-dependent telomere-independent PLB has been described in keratinocytes (33) , it is important to note that in this example the barrier is not the initial (M1) senescence but rather a downstream PLB (with M1 involving instead p16INKA/pRB). Overexpression of wild-type cyclin-dependent kinase 4 in HDFs allows these cells to escape M1 through hyperphosphorylation of pRB (34) . Our preliminary data (not shown) indicates that NHAs expressing wt CDK4 remain in M1, implying that M1 is a pRB-independent event. Therefore, NHAs are novel for providing a human example of a cell type that naturally undergoes p53-dependent telomere-independent senescence.

A Second Telomere-independent PLB in NHAs Involving p16INK4A.
Abrogation of p53 function confers life span extension but is insufficient to immortalize NHAs. Instead, E6-expressing NHAs eventually reach a second PLB we term MINT. A similar intermediate PLB has been demonstrated in E6-expressing HDFs (12) , and in this example, MINT is characterized by a ~3-fold increase in p16INK4A expression compared with its level in M1. Although a modest increase in p16INK4A is seen in MINT versus M1 astrocytes, the most compelling evidence for a role of p16INK4A in MINT comes from the analysis of rare spontaneous clones that escape MINT. To date, every independent escapee from MINT in NHAs grown in astrocyte medium has been associated with complete loss of detectable p16INK4A expression. Thus, although it remains unclear if up-regulation of p16INK4A is causal in the MINT growth arrest, it seems likely that loss of p16INK4A expression allows cells to reenter proliferation. Analysis of the promoter region of p16INK4A suggests that down-regulation of protein levels are caused by extensive methylation, a phenomenon frequently observed in tumors, including gliomas (35) .

Another difference is seen between NHAs and other cell types when considering p27KIP1. Our previous studies have shown that primary thyrocytes senesce with high levels of p27KIP1. Expression of an activated form of Ha-RAS allows thyrocytes to bypass senescence and is associated with a reduction of p27KIP1 expression. In contrast, no changes in p27KIP1 expression are seen in NHA.E6 cells that emerge from MINT.

The nature of the cell division counter that triggers MINT in NHAs remains unknown. Although in some fibroblast strains MINT can be bypassed by forced expression of telomerase (36) this does not appear to be the case in NHAs, because MINT still occurs in clones expressing both hTERT and E6. This second PLB thus appears to be telomere-independent, and can be bypassed by spontaneous loss of p16INK4A expression.

A Third PLB in NHAs That Is Telomere Driven.
A third PLB is eventually reached by NHAs that have escaped MINT. Such cells continued to proliferate with no additional intermediate arrest states until they reached a crisis-like state some 30 pd later. Overall, the combined effect of E6 expression and p16INK4A loss can add ~40 pd to the life span of NHAs. In parallel experiments using NHA.E6 cells that also express hTERT, escape from MINT was again seen. However, in this case, no subsequent entry into crisis was evident, but rather the cells continued to proliferate indefinitely, and have now undergone sufficient additional divisions (>170 pd) that we consider them immortal. Thus, this third crisis-like PLB appears to be telomere driven and, as such, would mirror the M2 crisis seen in fibroblasts when both the p53 and pRB pathways have been abrogated.

A Representative in Vitro Model of Multistep Human Glioma Development.
Although highly malignant tumors derived from astrocytes can appear to arise de novo, there is commonly a well-defined progression from the potentially curable benign grade I lesion through increasing degrees of malignancy, defined on pathological criteria as grade II (low-grade), grade III (anaplastic), and ultimately grade IV (glioblastoma multiforme).

This is associated with the stepwise accumulation of genetic abnormalities, a common sequence (1) , being, in grade I–IV, respectively: (a) growth factor and/or receptor overexpression (presumably the initiating event); (b) p53 mutation; (c) disruption of the Rb pathway (frequently through loss of p16 expression); and (d) telomerase activation.

As indicated in Fig. 8Citation , this is provocatively consistent with the sequence of events in our in vitro model, wherein exposure to high levels of growth factor (particularly platelet-derived growth factor and epidermal growth factor) in culture medium initially switches on proliferation, analogous to the endogenous stimulation provided by growth factor (receptor) overexpression in vivo, after which there is a series of PLBs overcome successively by experimental abrogation of p53, spontaneous loss of p16 through promoter methylation, and finally telomerase (hTERT) expression.



View larger version (25K):
[in this window]
[in a new window]
[Download PPT slide]
 
Fig. 8. A model of multistep tumorigenesis in human astrocytes. In vitro (A), normal astrocytes induced to proliferate by exogenous growth factors encounter a succession of PLBs that can be overcome by the indicated experimentally induced or spontaneous genetic events, leading to successive waves of clonal expansion. This series of molecular events correlates strikingly with the consensus sequence of genetic abnormalities observed in grade I–IV gliomas in vivo (B). See text for discussion.

 
This correlation leads to the novel suggestion that in vivo as well as in vitro the primary selective pressure for loss of p53 and pRB pathways might be the need to escape such innate restrictions on proliferative life span.

If so, this raises the interesting possibility that at least some of the classic clinicopathological features of malignant progression in this tumor type, increasing growth rate and invasiveness, might simply be explained as secondary results of the overall relaxation of growth control consequent on loss of these inhibitory pathways.

In summary, we propose a tumor model consistent with the molecular genetics of glioma development and a new addition to the existing array of PLBs in human cells, namely a p53 dependent, telomere-independent induced state of growth arrest. The nature of the signal that activates p53 to impose this barrier is unclear.


    ACKNOWLEDGMENTS
 
We thank Jane Bond and Michele Haughton for technical advice and support.


    FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by a Cancer Research UK studentship (to R. J. E.) and program grant (to D.W-T., D. K.). Back

2 Joint senior authors. Back

3 To whom requests for reprints should be addressed, at Department of Pathology, University of Wales College of Medicine, Heath Park, Cardiff CF14 4XN, United Kingdom. Phone: 44-29-20-744849; Fax: 44-29-20-745121; E-mail: Jonescj{at}cf.ac.uk Back

4 The abbreviations used are: NHA, normal human astrocyte; PLB, proliferative life span barrier; HDF, human diploid fibroblast; pd, population doubling; HPV, human papillomavirus; SA ß-gal, senescence-associated ß-galactosidase; BrdUrd, bromodeoxyuridine; LI, labeling index; TRAP, telomeric repeat amplification protocol; TRF, terminal restriction fragment. Back

Received 2/28/03. Revised 5/23/03. Accepted 6/ 4/03.


    REFERENCES
 Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Zhu Y., Parada L. F. The molecular and genetic basis of neurological tumours. Nat. Rev. Cancer, 2: 616-626, 2002.[Medline]
  2. Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp. Cell Res., 37: 614-636, 1965.[Medline]
  3. Campisi J. Normal somatic cells divide a limited number of times in vitro before entering a non-dividing state called senescence (M1). Cell, 84: 497-500, 1996.[Medline]
  4. Wright W. E., Pereira-Smith O. M., Shay J. W. Reversible cellular senescence: implications for immortalization of normal human diploid fibroblasts. Mol. Cell. Biol., 9: 3088-3092, 1989.[Abstract/Free Full Text]
  5. Bryan T. M., Reddel R. R. SV40-induced immortalization of human cells. Crit. Rev. Oncog., 5: 331-357, 1994.[Medline]
  6. Counter C. M., Avilion A. A., LeFeuvre C. E., Stewart N. G., Greider C. W., Harley C. B., Bacchetti S. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J., 11: 1921-1929, 1992.[Medline]
  7. Shay J. W., Wright W. E., Brasiskyte D., Van der Haegen B. A. E6 of human papillomavirus type 16 can overcome the M1 stage of immortalization in human mammary epithelial cells but not in human fibroblasts. Oncogene, 8: 1407-1413, 1993.[Medline]
  8. Foster S. A., Galloway D. A. Human papillomavirus type 16 E7 alleviates a proliferation block in early passage human mammary epithelial cells. Oncogene, 12: 1773-1779, 1996.[Medline]
  9. Bacchetti S. Telomere dynamics and telomerase activity in cell senescence and cancer. Cell Dev. Biol., 7: 31-39, 1996.
  10. Bryan T. M., Englezou A., Gupta J., Bacchetti S., Reddel R. R. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J., 14: 4240-4248, 1995.[Medline]
  11. Bodnar A. G., Ouellette M., Frolkis M., Holt S. E., Chiu C. P., Morin G. B., Harley C. B., Shay J. W., Lichtsteiner S., Wright W. E. Extension of life-span by introduction of telomerase into normal human cells. Science (Wash. DC), 279: 349-352, 1998.[Abstract/Free Full Text]
  12. Bond J. A., Haughton M. F., Rowson J. M., Smith P. J., Gire V., Wynford-Thomas D., Wyllie F. S. Control of replicative life span in human cells: barriers to clonal expansion intermediate between M1 senescence and M2 crisis. Mol. Cell. Biol., 19: 3103-3114, 1999.[Abstract/Free Full Text]
  13. Rogan E. M., Bryan T. M., Hukku B., Maclean K., Chang A. C., Moy E. L., Englezou A., Warneford S. G., Dalla-Pozza L., Reddel R. R. Alterations in p53 and p16INK4 expression and telomere length during spontaneous immortalization of Li-Fraumeni syndrome fibroblasts. Mol. Cell. Biol., 15: 4745-4753, 1995.[Abstract]
  14. Wyllie F. S., Jones C. J., Skinner J. W., Haughton M. F., Wallis C., Wynford-Thomas D., Faragher R. G., Kipling D. Telomerase prevents the accelerated cell aging of Werner syndrome fibroblasts. Nat. Genet., 24: 16-17, 2000.[Medline]
  15. McSharry B. P., Jones C. J., Skinner J. W., Kipling D., Wilkinson G. W. Human telomerase reverse transcriptase-immortalized MRC-5 and HCA2 human fibroblasts are fully permissive for human cytomegalovirus. J. Gen. Virol., 82: 855-863, 2001.[Abstract/Free Full Text]
  16. Dimri G. P., Lee X., Basile G., Acosta M., Scott G., Roskelley C., Medrano E. E., Linskens M., Rubelj I., Pereira-Smith O., et al A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. USA, 92: 9363-9367, 1995.[Abstract/Free Full Text]
  17. Bond J. A., Blaydes J. P., Rowson J., Haughton M. F., Smith J. R., Wynford-Thomas D., Wyllie F. S. Mutant p53 rescues human diploid cells from senescence without inhibiting the induction of SDI1/WAF1. Cancer Res., 55: 2404-2409, 1995.[Abstract/Free Full Text]
  18. Jones C. J., Soley A., Skinner J. W., Gupta J., Haughton M. F., Wyllie F. S., Schlumberger M., Bacchetti S., Wynford-Thomas D. Dissociation of telomere dynamics from telomerase activity in human thyroid cancer cells. Exp. Cell Res., 240: 333-339, 1998.[Medline]
  19. Vojtesek B., Bartek J., Midgley C. A., Lane D. P. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J. Immunol. Methods, 151: 237-244, 1992.[Medline]
  20. Lukas J., Parry D., Aagaard L., Mann D. J., Bartkova J., Strauss M., Peters G., Bartek J. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature (Lond.), 375: 503-506, 1995.[Medline]
  21. Herman J. G., Graff J. R., Myohanen S., Nelkin B. D., Baylin S. B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA, 93: 9821-9826, 1996.[Abstract/Free Full Text]
  22. Stephens P., Cook H., Hilton J., Jones C. J., Haughton M. F., Wyllie F. S., Skinner J. W., Harding K. G., Kipling D., Thomas D. W. An analysis of replicative senescence in dermal fibroblasts derived from chronic leg wounds predicts that telomerase therapy would fail to reverse their disease-specific cellular and proteolytic phenotype. Exp. Cell Res., 283: 22-35, 2003.[Medline]
  23. Bond J. A., Oddweig Ness G., Rowson J., Ivan M., White D., Wynford-Thomas D. Spontaneous de-differentiation correlates with extended life span in transformed thyroid epithelial cells: an epigenetic mechanism of tumour progression?. Int. J. Cancer, 67: 563-572, 1996.[Medline]
  24. Rich J. N., Guo C., McLendon R. E., Bigner D. D., Wang X. F., Counter C. M. A genetically tractable model of human glioma formation. Cancer Res., 61: 3556-3560, 2001.[Abstract/Free Full Text]
  25. Jones C. J., Kipling D., Morris M., Hepburn P., Skinner J., Bounacer A., Wyllie F. S., Ivan M., Bartek J., Wynford-Thomas D., Bond J. A. Evidence for a telomere-independent "clock" limiting RAS oncogene-driven proliferation of human thyroid epithelial cells. Mol. Cell. Biol., 20: 5690-5699, 2000.[Abstract/Free Full Text]
  26. Sonoda Y., Ozawa T., Hirose Y., Aldape K. D., McMahon M., Berger M. S., Pieper R. O. Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. Cancer Res., 61: 4956-4960, 2001.[Abstract/Free Full Text]
  27. Halvorsen T. L., Beattie G. M., Lopez A. D., Hayek A., Levine F. Accelerated telomere shortening and senescence in human pancreatic islet cells stimulated to divide in vitro. J. Endocrinol., 166: 103-109, 2000.[Abstract]
  28. Kiyono T., Foster S. A., Koop J. I., McDougall J. K., Galloway D. A., Klingelhutz A. J. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature (Lond.), 396: 84-88, 1998.[Medline]
  29. Ramirez R. D., Morales C. P., Herbert B. S., Rohde J. M., Passons C., Shay J. W., Wright W. E. Putative telomere-independent mechanisms of replicative aging reflect inadequate growth conditions. Genes Dev., 15: 398-403, 2001.[Abstract/Free Full Text]
  30. Belair C. D., Yeager T. R., Lopez P. M., Reznikoff C. A. Telomerase activity: a biomarker of cell proliferation, not malignant transformation. Proc. Natl. Acad. Sci. USA, 94: 13677-13682, 1997.[Abstract/Free Full Text]
  31. Wyllie F. S., Lemoine N. R., Barton C. M., Dawson T., Bond J., Wynford-Thomas D. Direct growth stimulation of normal human epithelial cells by mutant p53. Mol. Carcinog., 7: 83-88, 1993.[Medline]
  32. Kang M. K., Guo W., Park N. H. Replicative senescence of normal human oral keratinocytes is associated with the loss of telomerase activity without shortening of telomeres. Cell Growth Differ., 9: 85-95, 1998.[Abstract]
  33. Rheinwald J. G., Hahn W. C., Ramsey M. R., Wu J. Y., Guo Z., Tsao H., De Luca M., Catricala C., O’Toole K. M. A two-stage, p16(INK4A)- and p53-dependent keratinocyte senescence mechanism that limits replicative potential independent of telomere status. Mol. Cell. Biol., 22: 5157-5172, 2002.[Abstract/Free Full Text]
  34. Morris M., Hepburn P., Wynford-Thomas D. Sequential extension of proliferative life span in human fibroblasts induced by overexpression of CDK4 or 6 and loss of p53 function. Oncogene, 21: 4277-4288, 2002.[Medline]
  35. Herman J. G., Merlo A., Mao L., Lapidus R. G., Issa J. P., Davidson N. E., Sidransky D., Baylin S. B. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res., 55: 4525-4530, 1995.[Abstract/Free Full Text]
  36. Davis T., Singhrao S. K., Wyllie F. S., Haughton M. F., Smith P. J., Wiltshire M., Wynford-Thomas D., Jones C. J., Faragher R. G. A., Kipling D. Telomere-based proliferative life span barriers in Werner syndrome fibroblasts involve both p53-dependent and p53-independent mechanisms. J. Cell Sci., 116: 1349-1357, 2003.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
DevelopmentHome page
N. M. Walton, B. M. Sutter, H.-X. Chen, L.-J. Chang, S. N. Roper, B. Scheffler, and D. A. Steindler
Derivation and large-scale expansion of multipotent astroglial neural progenitors from adult human brain
Development, September 15, 2006; 133(18): 3671 - 3681.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. D. Henson, J. A. Hannay, S. W. McCarthy, J. A. Royds, T. R. Yeager, R. A. Robinson, S. B. Wharton, D. A. Jellinek, S. M. Arbuckle, J. Yoo, et al.
A Robust Assay for Alternative Lengthening of Telomeres in Tumors Shows the Significance of Alternative Lengthening of Telomeres in Sarcomas and Astrocytomas
Clin. Cancer Res., January 1, 2005; 11(1): 217 - 225.
[Abstract] [Full Text] [PDF]


Home page
ScienceHome page
D. Kipling, T. Davis, E. L. Ostler, and R. G. A. Faragher
What Can Progeroid Syndromes Tell Us About Human Aging?
Science, September 3, 2004; 305(5689): 1426 - 1431.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
A. Broniscer and A. Gajjar
Supratentorial High-Grade Astrocytoma and Diffuse Brainstem Glioma: Two Challenges for the Pediatric Oncologist
Oncologist, April 1, 2004; 9(2): 197 - 206.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Evans, R. J.
Right arrow Articles by Jones, C. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Evans, R. J.
Right arrow Articles by Jones, C. J.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online